BioNTech (NASDAQ:BNTX) Sees Large Volume Increase – Time to Buy?

BioNTech SE Sponsored ADR (NASDAQ:BNTX) saw unusually-high trading volume on Thursday . 774,507 shares changed hands during trading, a decline of 27% from the previous session’s volume of 1,066,491 shares.The stock last traded at $109.69 and had previously closed at $113.12.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech highlighted continued momentum in its late-stage lung-cancer program and plans to present new clinical data at the IASLC 2026 World Conference on Lung Cancer. The company will also report the first global data for the pumitamig/elfetabart drozuntecan combination, giving investors a potential catalyst for its non-COVID oncology strategy. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data
• Neutral Sentiment: BioNTech’s earlier rally followed positive topline data from Moderna and Merck involving individualized cancer therapy for advanced skin cancer. The reaction reflects investor interest in the broader cancer-vaccine opportunity, but Moderna’s results do not directly establish the efficacy of BioNTech’s programs. Why Is BioNTech Stock Surging on Wednesday?
• Negative Sentiment: Moderna’s sharp reversal after its prior surge is weighing on related cancer-vaccine stocks, including BioNTech. The move suggests investors are locking in gains and questioning whether the sector’s initial enthusiasm was excessive. Moderna Sinks After Cancer Vaccine Rally
• Negative Sentiment: Leerink analysts cautioned that BioNTech’s rally based on Moderna’s trial success may fade, reinforcing concerns that the stock’s recent gains were driven more by sector sentiment than company-specific clinical results. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BNTX shares. Wells Fargo & Company reduced their price target on shares of BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Price Performance

The company has a market cap of $28.19 billion, a P/E ratio of -14.24 and a beta of 1.27. The firm’s 50-day moving average is $92.48 and its two-hundred day moving average is $95.66. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same quarter last year, the business earned ($1.60) EPS. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

BioNTech announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC increased its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. EFG International AG bought a new stake in shares of BioNTech in the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after purchasing an additional 305 shares during the period. Finally, Vestcor Inc bought a new position in shares of BioNTech during the 4th quarter valued at approximately $153,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.